Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia.
Boldrin E, Gaffo E, Niedermayer A, Boer JM, Zimmermann M, Weichenhan D, Claus R, Münch V, Sun Q, Enzenmüller S, Seyfried F, Demir S, Zinngrebe J, Cario G, Schrappe M, Den Boer ML, Plass C, Debatin KM, Te Kronnie G, Bortoluzzi S, Meyer LH. Boldrin E, et al. Among authors: meyer lh. Blood. 2021 Nov 18;138(20):1953-1965. doi: 10.1182/blood.2020007591. Blood. 2021. PMID: 34098582 Free article.
Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation.
Lázaro-Navarro J, Pimentel-Gutiérrez HJ, Gauert A, Hagemann AIH, Eisenschmid J, Gökbuget N, Vick B, Jeremias I, Seyfried F, Meyer LH, Debatin KM, Richer K, Bultman M, Neumann M, Hänzelmann S, Serve H, Astrahantseff K, Rieger MA, Eckert C, Baldus CD, Bastian L. Lázaro-Navarro J, et al. Among authors: meyer lh. Blood Adv. 2021 Dec 28;5(24):5501-5506. doi: 10.1182/bloodadvances.2021004513. Blood Adv. 2021. PMID: 34610112 Free PMC article. No abstract available.
Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.
Jebaraj BMC, Müller A, Dheenadayalan RP, Endres S, Roessner PM, Seyfried F, Walliser C, Wist M, Qi J, Tausch E, Mertens D, Fox JA, Debatin KM, Meyer LH, Taverna P, Seiffert M, Gierschik P, Stilgenbauer S. Jebaraj BMC, et al. Among authors: meyer lh. Blood. 2022 Feb 10;139(6):859-875. doi: 10.1182/blood.2021011516. Blood. 2022. PMID: 34662393 Free article.
Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling.
Seyfried F, Demir S, Hörl RL, Stirnweiß FU, Ryan J, Scheffold A, Villalobos-Ortiz M, Boldrin E, Zinngrebe J, Enzenmüller S, Jenni S, Tsai YC, Bornhauser B, Fürstberger A, Kraus JM, Kestler HA, Bourquin JP, Stilgenbauer S, Letai A, Debatin KM, Meyer LH. Seyfried F, et al. Among authors: meyer lh. Cell Death Dis. 2019 Jul 29;10(8):571. doi: 10.1038/s41419-019-1801-0. Cell Death Dis. 2019. PMID: 31358732 Free PMC article.
Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation.
Enzenmüller S, Niedermayer A, Seyfried F, Muench V, Tews D, Rupp U, Tausch E, Groß A, Fischer-Posovszky P, Walther P, Stilgenbauer S, Kestler HA, Debatin KM, Meyer LH. Enzenmüller S, et al. Among authors: meyer lh. Cell Death Dis. 2024 Jul 3;15(7):475. doi: 10.1038/s41419-024-06864-7. Cell Death Dis. 2024. PMID: 38961053 Free PMC article.
59 results